EL7.AI
StocksMediumUpdated×3•Originally published 7 August 2026•Updated 7 August 2026•
1 min read

Mixed Results for Under Armour and Strong Double Beat for ANI Pharmaceuticals

Key Facts

1Under Armour reported Non-GAAP EPS of $0.05, beating estimates by $0.03.
2Under Armour revenue reached $1.1B, missing analyst estimates by $10M.
3ANI Pharmaceuticals beat both EPS and revenue estimates, with EPS reaching $2.21.

Reflecting a shift in consumer and healthcare sector dynamics, Under Armour and ANI Pharmaceuticals released their quarterly results for the period ending in 2026. Under Armour reported a Non-GAAP EPS of $0.05, beating analyst estimates by $0.03, though its $1.1B in revenue missed expectations by $10M. Conversely, ANI Pharmaceuticals delivered a robust performance, exceeding both earnings and revenue forecasts with an EPS of $2.21.

Per market data and financial reports, Under Armour's North American revenue declined by 9% to $610 million, while international revenue grew by 5% to $490 million. This mixed performance coincides with broader consumer trends, as the Michigan Consumer Sentiment index reached 55.2 at the end of July 2026, slightly higher than the forecasted 54, indicating a complex environment for retail and pharmaceutical growth.

Looking ahead, upcoming trade balance data from the United States will be a key catalyst to watch for its impact on multinational corporate earnings and global demand patterns.

Latest Updates · 2

  1. Notable·

    Update: Under Armour slashed its full-year revenue outlook following a sales decline in the fiscal first quarter, causing its shares to slip approximately 2% after the cautious guidance. This revision highlights ongoing pressure on top-line growth despite the company's recent earnings beat.

  2. Notable·

    Update: Under Armour has lowered its annual revenue guidance, forecasting a steeper decline than previously anticipated. The company attributed this downward revision to persistent weakness in consumer spending across its core North American market and ongoing macroeconomic uncertainty.